Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Entera Bio Ltd. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 9 | 12 | +3 |
| Shares | 4.66M | 3.05M | −1.61M (−34.6%) |
| Value | $4.85M | $415.9K | −$4.44M (−91.4%) |
New holders (3)
Institutions that held Entera Bio Ltd. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 30,465 | $22.2K | 0.00% |
| HRT Financial LP | 15,236 | $11.0K | 0.00% |
| BlackRock Inc. | 500 | $365 | 0.00% |
Sold out (0)
Institutions that held Entera Bio Ltd. at the end of Q3 2022 and filed for Q4 2022 without it.
None.